Mahzi Therapeutics Wins FDA Rare Pediatric Disease Designation
South San Francisco, California, August 25, 2026 Mahzi Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...
Phase 1/2
Advertisement
BlossomHill Therapeutics Gains FDA Fast Track for BH-30643
San Diego, California, August 18, 2026 BlossomHill Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Star Therapeutics to Present Phase 1/2 VGA039 Data at ISTH 2026
SOUTH SAN FRANCISCO, Calif., June 26, 2026 Star Therapeutics announced it will present complete safety and efficacy data from...
Taysha Gene Therapies Showcases TSHA-102 Progress at 2026 IRSF Meeting
DALLAS, June 25, 2026 Taysha Gene Therapies announced multiple presentations highlighting the clinical progress of its investigational TSHA-102 gene...
Tangram Advances TGM-312 With Phase 1/2 CTA Submission
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
Advertisement
